Cargando…
Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet
BYL719 (alpelisib) is a small molecule inhibitor of PI3K p110α developed for cancer therapy. Targeted suppression of PI3K has led to lifespan extension in rodents and model organisms. If PI3K inhibitors are to be considered as an aging therapeutic, it is important to understand the potential consequ...
Autores principales: | Hedges, Christopher P., Boix, Jordi, Jaiswal, Jagdish K., Shetty, Bhoopika, Shepherd, Peter R., Merry, Troy L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911305/ https://www.ncbi.nlm.nih.gov/pubmed/33503847 http://dx.doi.org/10.3390/biom11020150 |
Ejemplares similares
-
Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2019) -
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021) -
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs
por: Boyd, David C., et al.
Publicado: (2023) -
Prolonged treatment with a PI3K p110α inhibitor causes sex- and tissue-dependent changes in antioxidant content, but does not affect mitochondrial function
por: Hedges, Christopher P., et al.
Publicado: (2020) -
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
por: Chuang, Fu-Cheng, et al.
Publicado: (2021)